RenMice 기반 항체 개발 플랫폼

RenNano®

RenNano 마우스는 in vitro에서 인간화가 필요 없는 중쇄 단항체(HCAbs)를 생성하여, 더 빠르고 비용 효율적인 프로세스를 제공합니다. RenNano 유래 HCAbs는 서열 다양성, 최적의 친화성 및 유리한 약리학적 특성을 보여줍니다.

이 페이지에서

  • FR2-Camelized RenNano® Mice
  • Fully human RenNano® Mice
  • FAQs

출판물

    FR2-Camelized RenNano® Mice

    In human heavy chains, FR2 residues at positions 37, 44, 45, and 47 (Martin numbering) form part of the VH-VL interface. These residues are typically hydrophobic and are represented by the VGLW (Val-Gly-Leu-Trp) motif, which is normally buried through pairing with the light chain (Sang et al., 2022, Structure). In a heavy-chain-only or VHH format, however, these positions become more solvent-exposed. The exposed hydrophobic surface can increase unwanted interactions and aggregation, potentially reducing soluble expression and complicating candidate development.
    FR2 camelization replaces the human VGLW motif with the camelid-associated FERF (Phe-Glu-Arg-Phe) motif, making the exposed interface more hydrophilic to reduce aggregation risk and improve candidate developability.
    Comparative studies have shown that humanized libraries incorporating FERF can achieve higher screening success rates for viable lead candidates than libraries based on human VGLW (Arras et al., 2023, mAbs). Our in-house data further show that clinical-stage VHHs retaining camelid FR2 signatures exhibit higher expression yields and greater thermostability than those carrying the human VGLW motif.
    FR2-Camelized RenNano® Mice img

    Combining Fully Human and FR2-Camelized Human V Genes to Maximize HCAb Discovery Potential

    Building on our proprietary RenNano® mouse platform for human heavy-chain-only antibody (HCAb) discovery, next-generation RenNano® mice retain the original, fully intact human V gene repertoire while incorporating dozens of engineered framework region 2 (FR2)-camelized human V gene segments.
    This expanded repertoire increases sequence and framework diversity and is designed to improve discovery success and broaden epitope coverage.
    Engineering Strategy of Next-Generation RenNanoR Mice img

    Strategic Advantages of FR2-Camelized RenNano® Mice

    Reduced Aggregation Risk & Enhanced Developability

    Reduced Aggregation Risk & Enhanced Developability img
    The more hydrophilic FERF framework helps reduce unwanted hydrophobic interactions and aggregation risk, supporting improved solubility, lower nonspecific binding, better overall developability, and higher lead identification success.

    Dual-Engine Sequence Diversity

    Dual-Engine Sequence Diversity img
    Combines intact human V genes (VGLW) with engineered FR2-camelized human V genes (FERF), expanding candidate diversity across hard-to-target epitopes.

    Preserved Fully Human Potential

    Preserved Fully Human Potential img
    Retains the original human V gene repertoire, allowing discovery campaigns to continue generating fully human VHHs when unmodified human sequences are preferred.

    In Vivo Affinity Maturation

    In Vivo Affinity Maturation img
    Enables natural in vivo affinity maturation to generate high-affinity VHH leads, streamlining downstream optimization.

    Immune Phenotype and Antibody Repertoire

    Preserved B-Cell Development and Immune Cell Profiles
    FR2-camelized RenNano® mice showed B-cell development and splenic B-, T-, and NK-cell proportions comparable to those of the fully human RenNano® mice, supporting an expanded V gene repertoire while maintaining similar immune cell profiles.
    Preserved B-Cell Development and Immune Cell Profiles img
    Diverse V(D)J Rearrangements and Broad CDR3 Length Distribution
    NGS analysis of peripheral blood from unimmunized FR2-camelized RenNano® mice showed that nearly all FR2-camelized V gene segments participated in V(D)J recombination. D and J gene usage and CDR3 length distributions were similar to those observed in the fully human RenNano® mice.
    Diverse V(D)J Rearrangements and Broad CDR3 Length Distribution img

    FR2 Camelization Improves Soluble VHH Expression

    Higher Success Rate
    Proportion of VHHs successfully expressed in soluble form in E. coli
    63.6%
    ( 7/11 )
    Fully Human
    100%
    ( 10/10 )
    FR2 Camelized
    Greater Yield img
    FR2 camelization significantly improves soluble VHH expression in E. coli, achieving a 100% expression success rate and markedly higher expression yields.
    VHHs derived from RenNano® mice were expressed in E. coli and purified in-house. Data are presented as the median and interquartile range.

    FR2-Camelized Human HCAbs Show Significantly Enhanced Hydrophilicity

    FR2-Camelized Human HCAbs Show Significantly Enhanced Hydrophilicity img
    Hydrophobic interaction chromatography (HIC) analysis demonstrates that FR2-camelized HCAbs exhibit significantly shorter retention times, indicating markedly enhanced surface hydrophilicity and a more favorable solubility profile. RenNano®-derived HCAbs were expressed in CHO cells and purified in-house. Data are presented as the median and interquartile range.

    FR2-Camelized VHHs Exhibit Markedly Improved Monomer Purity

    Percentage of VHHs Meeting Monomer Purity Thresholds
    Percentage of VHHs Meeting Monomer Purity Thresholds img
    FR2-camelized VHHs demonstrate improved monomer purity, with a significantly higher proportion of clones meeting stringent purity thresholds (>80%, >90%, and >95%). RenNano®-derived VHHs were expressed in CHO cells or yeast and purified in-house. All 11 fully human VHHs were expressed in yeast; among the 60 FR2-camelized VHHs, 10 were expressed in yeast and 50 in CHO cells.

    Case Studies: Expanding VHH Discovery with FR2 Camelization

    FR2-camelized RenNano® mice retain the intact fully human V gene repertoire while incorporating engineered FR2-camelized human V gene segments. Screening enriched FR2-camelized binders for CD28 and fully human binders for CD3, highlighting how the combined repertoires support candidate discovery across different targets.
    Both case studies used FR2-camelized RenNano® mice for immunization.
    Case Study 1  |  CD28

    CD28: Enrichment of FR2-Camelized Binders

    FR2 Camelization Confers an Advantages in CD28 HCAb Discovery
    Phage display screening of libraries derived from FR2-camelized RenNano® mice revealed strong enrichment of FR2-camelized sequences among CD28 binders (genetic ratio: 1:1).
    FR2 Camelization Confers an Advantsage in CD28 HCAb Discovery img
    FR2-camelized sequences increased from 27.0% in the initial library to 82.3% among antigen-positive clones after panning, despite an initial 1:1 germline ratio. FR2-camelized binders showed generally higher thermal stability and favorable HIC profiles, supporting the value of FR2 camelization in obtaining stable, binding-competent VHHs.
    Case Study 2  |  CD3

    CD3: Enrichment of Fully Human Binders

    Fully Human Germline-Derived Sequences Dominate CD3 HCAb Selection
    Phage display screening of libraries derived from FR2-camelized RenNano® mice revealed strong enrichment of fully human sequences among CD3 binders (genetic ratio: 1:1).
    Fully Human Germline-Derived Sequences Dominate CD3 HCAbs Selection img
    All selected CD3 binders originated from fully human germlines, and over 80% carried hydrophilicity-enhancing FR2 substitutions. HCAb-format characterization showed generally favorable thermal stability and HIC profiles. These findings highlight the retained potential for fully human VHH discovery in FR2-camelized RenNano® mice.
    CD3 HCAbs Show Diverse Binding and T-Cell Activation Profiles
    CD3 HCAbs Show Diverse Binding and T-Cell Activation Profiles img
    CD3 HCAbs with diverse binding affinities and T-cell activation profiles provide a range of candidates for different functional requirements.

    Fully Human RenNano® Mice

    RenNano® 마우스의 주요 특징

    1. 완전 인간형 중쇄 가변 영역과 수정된 상수 영역
    Fully human heavy chain variable region and modified constant region
    2. RenNano 마우스는 여러 항원에 대해 강력한 면역 반응을 보입니다
    TFR1, 4-1BB, and ALB img
    RenNano 마우스의 TFR1, 4-1BB, ALB에 대한 면역 반응. TFR-1과 4-1BB(막 항원)으로 면역한 RenNano 마우스의 혈청은 희석되어 항원 발현 CHO 세포와 인큐베이션되었습니다. 형광 표지된 2차 항체를 사용하여 CHO에 결합한 HCAb를 라벨링하고, 흐름 세포 분석을 통해 평균 형광 강도(MFI)를 측정하여 항원 특이적 HCAb의 titre를 나타냈습니다. ALB(분비 항원)로 면역한 RenNano 마우스의 혈청은 희석되어 형광 표지된 2차 항체와 인큐베이션되었습니다. ELISA를 사용하여 OD450을 측정하여 항원 특이적 HCAb의 titre를 나타냈습니다.
    3. RenNano 유래 항원 특이적 HCAb는 뛰어난 다양성을 보입니다
    RenNano-derived antigen-specific HCAbs img
    RenNano 마우스 유래 HCAb는 다양하며, 많은 수가 긴 CDR3 영역을 포함합니다. 항원 특이적 HCAb는 그들의 중쇄 종계 유전자 사용과 CDR3 길이에 따라 분석되었습니다. 분석 결과는 광범위한 IGHV 종계 다양성을 보여줍니다. 또한, 관찰된 대부분의 CDR3 길이는 12개 아미노산을 넘었으며, 일부는 17개 아미노산 이상이었습니다.

    RenNano® 마우스의 검증 데이터

    Binding affinity

    68개의 정제된 RenNano HCAb의 8개 타겟(4-1BB, TROP2, IL3RA, OX40, Nectin-4, ROR1, PSMA, DLL3)에 대한 친화도는 SPR로 테스트되었습니다. 대부분의 HCAb에서 KD는 10-6 ~ 10-10 M 범위였습니다.

    B cells (mCD19+ mCD3-) and Spleen FO/MZ-B

    RenNano 마우스의 B세포 발달 및 분화 패턴. RenNano 마우스는 외부 림프기관(비장, SP, 림프절, LN)에서 B세포 비율이 야생형 마우스 또는 RenMab 마우스와 비교하여 비슷합니다. RenNano 마우스의 비장에는 야생형 마우스나 RenMab 마우스와 비교하여 여포 B세포(FO-B)와 가장자리지대 B세포(MZ-B) 비율이 비슷합니다.

    RenNano-derived HCAbs demonstrate outstanding developability

    RenNano HCAb의 물리화학적 특성 분석. RenNano HCAb는 한 번의 정제 후 높은 순도를 보였습니다(A). HCAb는 HIC-HPLC 및 CIC-HPLC에서 짧은 유지 시간을 보여주며, 이는 뛰어난 친수성과 특이성을 나타냅니다(B, C). RenNano HCAb는 또한 우수한 열 안정성을 보였습니다(D).

    Frequently Asked Questions (FAQs) About RenNano

    1. What is a heavy-chain-only antibody (HCAb)?

    A heavy-chain-only antibody (HCAb) recognizes and binds an antigen without a light chain. Antigen recognition is mediated by its heavy-chain variable domain, known as a VHH, which can also function independently as a compact single-domain antibody. An HCAb includes additional heavy-chain regions, whereas an isolated VHH consists only of the antigen-binding domain.

    2. What is RenNano®, and how does it generate fully human HCAbs?

    RenNano® is Biocytogen’s fully human heavy-chain-only antibody (HCAb) discovery platform within the RenMice® family. It replaces mouse heavy-chain variable region with human V(D)J segments and engineers immunoglobulin loci to enable antibody production without light chains. Following immunization, RenNano® generates diverse fully human HCAbs that undergo natural recombination and immune selection directly in vivo.

    3. How do RenNano®-derived VHHs differ from camelid-derived VHHs?

    Camelid-derived VHHs originate from naturally occurring heavy-chain-only antibodies in animals such as llamas and alpacas. RenNano®-derived VHHs are generated in genetically engineered mice carrying a human heavy-chain variable repertoire. This enables RenNano® mice to directly generate fully human VHH antigen-binding sequences in vivo without the need for downstream antibody humanization.

    4. How does RenNano® support stable HCAb production while maintaining B-cell development?

    RenNano® combines constant-region and light-chain locus engineering to remove light-chain dependency while preserving the immunoglobulin functions required for B-cell receptor signaling, antibody assembly, and production. This enables stable HCAb production while maintaining overall normal B-cell development in RenNano® mice.

    5. How does RenNano® generate diverse and high-affinity HCAb candidates?

    RenNano® combines a fully human V(D)J repertoire with natural gene recombination to generate diverse HCAbs. Following immunization, somatic hypermutation and in vivo immune selection refine antibody binding through affinity maturation, supporting the discovery of high-affinity candidates. For suitable targets, RenNano® target-gene knockout mice can help overcome immune tolerance and expand epitope diversity.

    6. Why can extended CDR3 regions help HCAbs recognize difficult-to-access epitopes?

    The CDR3 forms part of an antibody’s antigen-binding site. In HCAbs, the absence of a paired light chain can allow longer CDR3 loops to extend into recessed pockets or otherwise difficult-to-reach epitopes. This helps VHH domains recognize challenging targets, including GPCRs and ion channels.